Study reveals trazodone dosing dangers for seniors with kidney trouble
NCT ID NCT07381101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined over 31,000 older adults (65+) with chronic kidney disease to see if starting a higher dose of the sleep medication trazodone (75-150 mg/day) leads to more serious events like hospital visits or death within 30 days compared to a lower dose (25-75 mg/day). The goal was to understand the safety of different trazodone doses in this vulnerable group. The study was observational, meaning it looked back at existing health records, and did not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
31,459 people
The number who actually took part.
- Started
-
Jan 2008
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults aged 66 years or older with low kidney function (eGFR \<45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) who have filled a new outpatient prescription for trazodone with a dose range of 25-150 mg/day and a day supply of ≥5 days between 2008 and 2025 in Ontario.
- Ages
-
66 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: The cohort will will include all older adults (≥66 years) with an eGFR \<45 mL/min per 1.73 m2 (not receiving dialysis or having a history of kidney transplantation) who received a new outpatient prescription for oral trazodone with an initial dose between 25 and 150 mg/day and a day supply of ≥5 days between January 1, 2008 to March 1, 2025. The age criterion is set to guarantee that individuals in this population have had at least one year of prior prescription drug coverage. The date when the prescription was filled will serve as the patient's entry or index date for the cohort, with each patient entering the cohort only once. Exclusion Criteria: 1. Individuals with missing administrative database number, missing or invalid age (\<0 or \>105 years), missing or invalid sex, death on or before the index date, non-Ontario resident (for Ontario data), or non-Alberta residents (for Alberta data). 2. Individuals less than 66 years of age on the index date. 3. Those with evidence of any study drug prescription 180 days before the index date (to restrict to new users only). 4. Individuals with more than one study drug prescription on the index date, as this complicates the ability to ascertain the prescribed dose accurately. 5. Individuals with end-stage renal disease, chronic dialysis, or a kidney transplant prior to the index date. 6. Evidence with hospital discharge or emergency department visit in the two days prior to or on the index date to ensure a new outpatient prescription. 7. Individuals with no serum creatinine lab value in the 0-365 days prior to the index date. 8. Individuals with unstable baseline kidney function: If the most recent serum creatinine test prior to the index date was an inpatient test \[ER or hospitalization\] \<refer to this as test date 1\>, and there is not at least one 'outpatient' serum creatinine in the year before test date 1, OR If the most recent prior serum creatinine test prior to the index date was an inpatient test \[ER or hospitalization\] \<refer to this as test date 1\>, and while there is at least 'outpatient' serum creatinine test in the year before \<test date 1\>, the most recent outpatient test prior to \<test date 1\> differs by an eGFR 10 mL/min/1.73 m2 or more from the value on \<test date 1\>. In Ontario, it has been shown that outpatient serum creatinine measurements in the province, conducted on a single occasion, indicate stable values. 9. Individuals receiving palliative care in the 0-365 days prior to the index date, in this setting, dosing is less relevant; rather, the focus is comfort care. The investigators restrict to the first prescription in individuals with more than one eligible prescription. Date of this prescription will be the index date (the Date from which the outcomes start being assessed).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease (CKD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
London Health Sciences Centre Research Institute
London, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can dance classes keep older adults steady on their feet?
- Higher domperidone doses under scrutiny for older kidney patients
- Does dialysis strip the body of essential metals?
- A 10-minute video may change how doctors treat malnutrition in the elderly
- Which dialysis method offers the best life and survival?
- Can big data unmask hidden clusters of cardiometabolic disease?